BioCentury
ARTICLE | Strategy

ImmunoGen rescues its product

July 19, 1993 7:00 AM UTC

ImmunoGen rescues its product ImmunoGen Inc. (IMGN), which has dropped Roussel-Uclaf as its European development and marketing partner for Oncolysin B, hopes to conclude a new partnership within nine to 18 months.

The company's lead product, mired in an unfinished Phase I European trial since 1991, is a year behind IMGN's U.S. product timetable, according to spokesperson Mark Ratner. However, Ratner said, Oncolysin B has become a more attractive project because of its advanced development in the U.S. "The drug has gone from a Phase I product to a Phase III product since we struck the deal with Roussel," he said. Oncolysin B is in Phase III U.S. trials for treatment of B-cell lymphoma. ...